55635-63-7

Basic information

• Product Name: 2,3-Pyrazinediamine,5-bromo-N3-methyl-
• Synonyms: 2-Amino-5-bromo-3-(methylamino)pyrazine
• CAS NO: 55635-63-7
• Molecular Formula: C₅H₇BrN₄
• Molecular Weight: 203.0399
• Product Categories: Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrazines
• Mol File: 55635-63-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 132-137 °C
• Boiling Point: 330.013 °C at 760 mmHg
• Flash Point: 153.386 °C
• Appearance: /
• Density: 1.784g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.7
• PKA: 2.93±0.10(Predicted)
• CAS DataBase Reference: 2,3-Pyrazinediamine,5-bromo-N3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Pyrazinediamine,5-bromo-N3-methyl-(55635-63-7)
• EPA Substance Registry System: 2,3-Pyrazinediamine,5-bromo-N3-methyl-(55635-63-7)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37-36
• WGK Germany: 3
• Hazardous Substances Data: 55635-63-7(Hazardous Substances Data)

Usage

General Description

"2,3-Pyrazinediamine,5-bromo-N3-methyl-" is a chemical compound known for its role in various research and experimental domains. It is categorized as a pyrazine and an aromatic amine, which means it contains a ring-shaped organic compound composed of four carbon atoms and two nitrogen atoms. Its distinct molecular structure, characterized by the addition of a bromine atom and a methyl group, contributes to its distinct properties and potential applications. However, specific details regarding its uses, safety measures, and regulations may vary and should be referenced from a certified and accurate chemical database or material safety data sheet. The compound's systematic IUPAC name is 5-bromo-N3-methylpyrazine-2,3-diamine.

InChI:InChI=1/C5H7BrN4/c1-8-5-4(7)9-2-3(6)10-5/h2H,1H3,(H2,7,9)(H,8,10)

Upstream product

• 67-56-1 methanol 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 74-89-5 methylamine 

Downstream Products

• 187344-68-9 6-bromo-3-(hydroxymethyl)-8-(methylamino)imidazo<1,2-a>pyrazine 
• 55635-64-8 6-bromo-1-methyl-1H-imidazo<4,5-b>pyrazine 

Relevant articles and documents

Design, Synthesis, and Molecular Docking Studies of Pyrazine Containing 1,2,3-Triazole Derivatives

Here, we demonstrate on the design and synthesis of novel pyrazine containing 1,2,3-triazole derivatives (7a, 7b, 7c, 7d, 8a, 8b, 8c, 8d, and 12a, 12b, 12c, 12d) using various chemicals, bases, and catalysts synthesized with excellent yields (78–92%) as described in the procedures. The development of this methodology is simple, efficient, and easier to handle; milder reaction conditions and higher selectivity under versatile coupling reagent useful for both amide and ester bond formations have also been developed. The synthesis of amide coupling derivatives prepared by (6a, 6b, 6c, 6d) was coupled with N-ethylpiperazine to afford (7a, 7b, 7c, 7d) and morpholine to afford (8a, 8b, 8c, 8d) by using 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIPEA) in dichloromethane at room temperature for 10 h. The derivatives (6a, 6b, 6c, 6d) were coupled with alcohol (11) by using N,N′-dicyclohexylcarbodiimide and 4-dimethylaminopyridine in dichloromethane (DCM) at room temperature for 16 h to give final compounds (12a, 12b, 12c, 12d). In silico docking approach has been applied to these compounds to screen their efficacy against selected drug targets of cancer and diabetes. The docking approach may facilitate the prediction of activity profile for future experimental findings.

HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y

Synthesis and Antibronchospastic Activity of 8-Alkoxy- and 8-(Alkylamino)imidazopyrazines

Theophylline still occupies a dominant place in asthma therapy.Unfortunatly its adverse central nervous system (CNS) stimulant effects can dramatically limit its use, and adjustments in the dosage are often needed.We have synthesized a new series of imidazopyrazine derivatives which are much more potent bronchodilators than theophylline in vivo and do not exhibit the CNS stimulatory profile.In vitro studies on isolated rat uterus and guinea pig trachea confirm the high potentialities of these derivatives. 6-Bromo-8-(methylamino)imidazopyrazine-3-carbonitrile (23) is identified as the most potent compound of the series.As i n the case of theophylline, phosphodiesterase inhibition appears unlikely to be the unique mechanism of the action of this series of heterocycles.